The clinical experience of DPP-4 inhibitor.

doi:10.7504/nk2014090204

Abstract

Abstract:

Abstract：Type 2 Diabetes Mellitus (T2DM) is exacting a high level of patient suffering and social cost worldwide.The past several decades witnessed intensive investigations on new lines of therapeutics regimen for T2DM.Among them，there is a new class of oral anti-hyperglycemic agent called dipeptidyl peptidase-4 inhibitor which includes Sitagliptin，Saxagliptin，Vildagliptin，Alogliptin and Linagliptin.In the current review，we are endeavored to provide a comprehensive overview on clinical and translational evidence of DPP-4 inhibitor action and the safety profile.Particularly，we are interested in reviewing evidence on the underlying mechanism for blood glucose control，micro and macro vascular benefits，clinical data which involves Sitagliptin as monotherapy and combined therapy and beneficial effects beyond blood glucose control.The data currently available strongly suggest DPP-4 inhibitor is an effective oral anti-hyperglycemic agent with optimal safety profile.Thus，it has been recommended by numerous high-impact guidelines as a major second-line (ADA，CDS) or even optional first-line for elderly T2DM patients (IDF).

Key words: DPP-4 inhibitor；efficacy；safety, type 2 diabetes mellitus

摘要：

2型糖尿病日益增长的患病率及疾病负担，使其成为世界范围内广为关注的慢性疾病。过去的几十年间，由于2型糖尿病治疗药物的深入研究，涌现了新一代的口服降糖药二肽基肽酶Ⅳ抑制剂(DPP-4 inhibitor)，其中包括西格列汀、沙格列汀、维格列汀、阿格列汀和利格列汀。文章就现有临床证据对DPP-4抑制剂的作用特点和安全性进行了系统的回顾。谨以西格列汀作为该类药物的代表，探讨了其潜在的降糖作用机制、降糖效应以外的对心血管系统可能存在的潜在效应及在单药和联合的降糖治疗方案中的临床试验数据。现有临床证据显示，DPP-4抑制剂是有效的口服降糖药，且具有良好的安全性。因此为众多高影响力的指南所推荐，并且是国际糖尿病联盟(IDF)老年人群2型糖尿病治疗指南中推荐的可选一线药物之一。

关键词: DPP-4抑制剂, 疗效, 安全性, 2型糖尿病

CLC Number:

ZOU Da-jin.. The clinical experience of DPP-4 inhibitor.[J]. Acta Metallurgica Sinica, DOI: 10.7504/nk2014090204.

邹大进. 二肽基肽酶Ⅳ抑制剂类降糖药的临床认识[J]. 中国实用内科杂志, DOI: 10.7504/nk2014090204.

References



[1］Xu Y，Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults［J］.JAMA，2013，310(9)：948-959. 

[2］Mohan V，Yang W,Son HY,et al.Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China，India，and Korea［J］.Diabetes Res Clin Pract，2009，83(1)：106-116. 

[3］Aschner P，Kiphes MS,Iunceford IK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes［J］.Diabetes Care，2006，29(12)：2632-2637. 

[4］Rosenstock J，Brazg R,Andryuk PJ,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes：a 24-week，multicenter，randomized，double-blind，placebo-controlled，parallel-group study［J］.Clin Ther，2006，28(10)：1556-1568. 

[5］Yang W，Guan Y,Shentu Y,et al.The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes［J］.J Diabetes，2012，4(3)：227-237. 

[6］Raz I，Chen Y,Wu M,et al.Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.Curr Med Res Opin，2008，24(2)：537-550. 

[7］Hermansen K，Kipnes M,Luo E,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor，sitagliptin，in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin［J］.Diabetes Obes Metab，2007，9(5)：733-745. 

[8］Dobs AS，Goldstein BJ,Aschner P,et al.Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes［J］.J Diabetes，2013，5(1)：68-79. 

[9］Vilsboll T，Rosenstock H,Yki-Jarrinen H,et al.Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes［J］.Diabetes Obes Metab，2010，12(2)：167-177. 

[10］Aschner P，Katzeff HL,Guo H,et al.Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes［J］.Diabetes Obes Metab，2010，12(3)：252-261. 

[11］Iwamoto Y，Tajima N,Kadouaki T,et al.Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes：a randomized，double-blind trial［J］.Diabetes Obes Metab，2010，12(7)：613-622. 

[12］Arechavaleta R，Seck T,Chen Y,et al.Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy：a randomized，double-blind，non-inferiority trial［J］.Diabetes Obes Metab，2011，13(2)：160-168. 

[13］Kim YG，Hahn s,Oh TJ,et al.Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians：a systematic review and meta-analysis［J］.Diabetologia，2013，56(4)：696-708. 

[14］Phung OJ，Scholle JM,Taluar M,et al.Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control，weight gain，and hypoglycemia in type 2 diabetes［J］.JAMA，2010，303(14)：1410-1418. 

[15］Scott R，Wu M,Sanchez M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes［J］.Int J Clin Pract，2007.61(1)：171-180. 

[16］Wainstein J，Katz L,Enqel SS,et al.Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes［J］.Diabetes Obes Metab，2012，14(5)：409-418. 

[17］U.K.prospective diabetes study 16.Overview of 6 years’ therapy of type Ⅱ diabetes：a progressive disease.U.K.Prospective Diabetes Study Group［J］.Diabetes，1995，44(11)：1249-1258. 

[18］Alba M，Ahren B,Inzucchi SE,et al.Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function［J］.Diabetes Obes Metab，2013，15(12)：1101-1110. 

[19］Maiztegui B，Boreli MI,Madrid VG,et al.Sitagliptin prevents the development of metabolic and hormonal disturbances，increased beta-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats［J］.Clin Sci (Lond)，2011，120(2)：73-80. 

[20］Riche DM， East HE， Riche KD.Impact of sitagliptin on markers of beta-cell function：a meta-analysis［J］.Am J Med Sci，2009，337(5)：321-328. 

[21］Ceriello A，Esposito K,Testa R,et al.The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes［J］.Diabetes Care，2011，34(3)：697-702. 

[22］Huang CY，Shih CM,Tsao NW,et al.Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells［J］.Br J Pharmacol，2012，167(7)：1506-1519. 

[23］Barbieri M，Rizzo MR,Marfella R,et al.Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-Ⅳ inhibitors［J］.Atherosclerosis，2013，227(2)：349-354. 

[24］Pacheco BP，Crajoinas RO,Couto GK,et al.Dipeptidyl peptidase Ⅳ inhibition attenuates blood pressure rising in young spontaneously hypertensive rats［J］.J Hypertens，2011，29(3)：520-528. 

[25］Ogawa S，Iahiki M,Nako K,et al.Sitagliptin，a dipeptidyl peptidase-4 inhibitor，decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes［J］.Tohoku J Exp Med，2011，223(2)：133-135. 

[26］Derosa G，Ragonesi PD,Fogari EF,et al.Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile：a 2-year study evaluation［J］.Fundam Clin Pharmacol，2014，28(2)：221-229. 

[27］Tremblay AJ，Iamarche B,Deacon CF,et al.Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes［J］.Diabetes Obes Metab，2011，13(4)：366-373. 

[28］Satoh-Asahara N，Sasaki Y,Wada H,et al.A dipeptidyl peptidase-4 inhibitor，sitagliptin，exerts anti-inflammatory effects in type 2 diabetic patients［J］.Metabolism，2013，62(3)：347-351. 

[29］Kowluru RA, Odenbach S.Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats［J］.Diabetes，2004，53(12)：3233-3238. 

[30］Liu WJ，Xie SH,Liu YN,et al.Dipeptidyl peptidase Ⅳ inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats［J］.J Pharmacol Exp Ther，2012，340(2)：248-255. 

[31］Vaghasiya J，Sheth N,Bhalodin Y,et al.Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes［J］.Regul Pept，2011，166(1-3)：48-54. 

[32］Patil HR，Badarn FJ,Shami HA,et al.Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus［J］.Am J Cardiol，2012，110(6)：826-833. 

[33］Engel SS，Golin GT,Shapiro D,et al.Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus：a pooled analysis［J］.Cardiovasc Diabetol，2013，12：3. 

[34］Ussher，JR, Drucker DJ.Cardiovascular actions of incretin-based therapies［J］.Circ Res，2014，114(11)：1788-1803. 

[35］Green JB，BETHEL ma,Paul SK,et al.Rationale，design，and organization of a randomized，controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease［J］.Am Heart J，2013，166(6)：983-989. 

[36］Liu L，LiuJ,Wong WT,et al.Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism［J］.Hypertension，2012，60(3)：p.833-841. 

[37］Xu Y，Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults［J］.JAMA，2013，310(9)：948-959. 

[38］Kyle KA，Willett TL,Baqqio LL,et al.Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice［J］.Endocrinology，2011，152(2)：457-467. 

[39］Hegazy SK.Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women［J］.J Bone Miner Metab，2014. 

[40］Barzilai N，Guo H,Mathoney EM,et al.Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes：a randomized，double-blind，placebo-controlled trial［J］.Curr Med Res Opin，2011，27(5)：p.1049-1058. 

[41］中国老年学学会老年医学会老年内分泌代谢专业委员会老年糖尿病诊疗措施专家共识编写组.老年糖尿病诊疗措施专家共识(2013年版)［J］.中华内科杂志，2014，53(3)：243-251. 

[1]	. [J]. Acta Metallurgica Sinica, 2014, 34(7): 714-715.
[2]	. [J]. Acta Metallurgica Sinica, 2014, 34(5): 516-517.
[3]	GU Guang-yu，ZHENG Shao-xiong.. SGLT2 inhibitors-new way for the treatment of type 2 diabetes. [J]. Acta Metallurgica Sinica, 2014, 34(10): 962-968.